Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Amgen has finally closed its $27.8 billion takeover of Horizon Pharma ... about antitrust intervention in its M&A transactions. Sales of Tepezza reached $851 million in the first half of 2023 ...

there are no disclosure requirements in relation to relevant securities of Amgen. Horizon derives almost half of its €3.4 billion ($3.6bn) in annual sales from Tepezza (teprotumumab), a ...

Amgen Inc (NASDAQ:AMGN) reported a 19% year-over-year increase in total revenues for 2024, driven by strong product sales growth ... interest expenses due to the Horizon acquisition.

For the full fiscal 2024, Amgen is expected to deliver ... Driven by a significant surge in volumes and the acquisition of Horizon Therapeutics, Amgen’s total revenues surged 23.2% year-over ...

Feb. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus ... Excluding sales from our Horizon Therapeutics (Horizon ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.